Tumorresponse monitoring in patients with breast cancer treated with primary systemic therapy: Towards predicting response in both the primary tumor and in axillary lymph nodes

Tumorresponse monitoring in patients with breast cancer treated with primary systemic therapy: Towards predicting response in both the primary tumor and in axillary lymph nodes - Tumorresponse monitoring of primary systemic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31961

Enrollment

300

Registered

2008-09-10

Start date

2008-07-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion in one of the clinical protocols that are part of the NKI-AVL neoadjuvant therapy program; women with breastcancer > 3 cm and/or axillary lymph node metastasis

Exclusion criteria

Exclusion criteria: Exclusion in one of the clinical protocols that are part of the NKI-AVL neoadjuvant therapy program; Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Sensitivity and specificity of FDG PET and MRI to assess early tumour response of the primary tumour Sensitivity and specificity of FDG PET/CT and seed localisation in measuring (early) tumour response of the axilla.	—

Countries

Netherlands

Outcome results